In our immunocompetent in vivo model of TAE, based on previously published mouse glioma cells that have ATRX and TP53 inactivation and are isogenic other than the presence or absence of IDHmut (38, 62), the IDHmut is only a passenger mutation, yet still produces D2HG. This evidence concerns the gene TP53 and central nervous system cancer.